| 40. |
SEGMENTAL ANALYSIS |
|
|
|
|
|
|
|
| |
|
|
June 2009 |
Restated
June 2008 |
% |
|
| |
|
|
R’million |
% of total |
R’million |
% of total |
change |
|
| |
Revenue |
|
|
|
|
|
|
|
| |
South Africa |
|
4 867,5 |
56 |
3 758,4 |
77 |
30 |
|
| |
International |
|
3 868,9 |
44 |
1 122,9 |
23 |
245 |
|
| |
Gross sales |
|
3 961,6 |
|
1 205,1 |
|
|
|
| |
Less: intersegment sales |
|
(92,7) |
|
(82,2) |
|
|
|
 |
|
|
|
|
|
|
|
|
| |
Total revenue |
|
8 736,4 |
100 |
4 881,3 |
100 |
79 |
|
| |
Less: revenue from discontinued operations |
|
(286,1) |
|
(198,8) |
|
|
|
| |
Total revenue from continuing operations |
|
8 450,3 |
|
4 682,5 |
|
80 |
|
| |
Operating profit before amortisation, disposals
and impairment of intangible assets from
continuing operations |
|
|
|
|
|
|
|
| |
South Africa |
|
1 226,6 |
53 |
1 067,2 |
85 |
15 |
|
| |
Operating profit |
|
1 169,7 |
|
1 036,6 |
|
|
|
| |
Amortisation of intangible assets |
|
37,8 |
|
68,2 |
|
|
|
| |
Profit on sale of Shimoda shares |
|
— |
|
(5,0) |
|
|
|
| |
Profit on sale of Formule Naturelle range |
|
— |
|
(40,8) |
|
|
|
| |
Impairment on intangible assets |
|
19,1 |
|
8,2 |
|
|
|
| |
International |
|
1 076,2 |
47 |
192,8 |
15 |
458 |
|
| |
Operating profit |
|
1 013,3 |
|
159,7 |
|
|
|
| |
Amortisation of intangible assets |
|
57,2 |
|
49,7 |
|
|
|
| |
Profit on sale of 51% of Co-pharma Ltd |
|
— |
|
(16,6) |
|
|
|
| |
Impairment on intangible assets |
|
5,7 |
|
— |
|
|
|
| |
|
|
2 302,8 |
100 |
1 260,0 |
100 |
83 |
|
| |
Operating profit before amortisation, disposals and impairment of intangible assets from continuing operations as a percentage of revenue |
|
% |
|
% |
|
|
|
| |
South Africa |
|
25,2 |
|
28,4 |
|
|
|
| |
International |
|
30,0 |
|
20,9 |
|
|
|
| |
|
|
27,3 |
|
26,9 |
|
|
|
| |
The Executive directors regularly review the operating results of the Group based on local and international businesses. |
| |
The amounts reviewed with respect to operating profits are measured in a manner consistent with that of the financial statements. |
| |
One customer accounts for more than 10% of the Group’s revenues (R1,1 billion – South African segment) (2008: R0,7 billion). |
| |
Entity wide disclosure |
|
|
|
|
|
|
|
| |
Geographical analysis of revenue |
|
|
|
|
|
|
|
| |
|
|
June 2009 |
Restated
June 2008 |
% |
|
| |
|
|
R’million |
% of total |
R’million |
% of total |
change |
|
| |
South Africa – pharmaceutical |
|
3 766,7 |
43 |
2 807,5 |
58 |
34 |
|
| |
South Africa – consumer |
|
1 100,8 |
13 |
950,9 |
19 |
16 |
|
| |
East Africa |
|
372,8 |
4 |
46,7 |
1 |
698 |
|
| |
Asia Pacific |
|
915,4 |
10 |
709,0 |
15 |
29 |
|
| |
Latin America |
|
841,3 |
10 |
82,9 |
2 |
915 |
|
| |
Global brands |
|
1 438,0 |
16 |
11,8 |
0 |
12 086 |
|
| |
Rest of the world |
|
301,4 |
4 |
272,5 |
5 |
11 |
|
| |
Total revenue |
|
8 736,4 |
100 |
4 881,3 |
100 |
79 |
|
| |
Less: Discontinued operations |
|
(286,1) |
|
(198,8) |
|
|
|
| |
Total revenue from continuing operations |
|
8 450,3 |
|
4 682,5 |
|
80 |
|
|
